Viewing data from:

ESTRADIOL VALERATE

ANDA

ESTRADIOL VALERATE | A040628 | FOSUN PHARMA USA INC

3 strengths0 unique patents0 unique exclusivities

Medicare Part D Spending

CMS annual spending data for Estradiol Valerate (2023)

Total Spending

$1.8M

Total Claims

11,988

Beneficiaries

4,078

Avg Cost/Unit

$26.31

Spending Trend

$312K(2020)→$972K(2021)→$1.4M(2022)→$1.8M(2023)

YoY Change:-6.7%

5yr CAGR:+2.4%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

API Supply Chain5 active DMFs2 inactive

5 active API suppliers hold Drug Master Files for this ingredient.

BAYER AGESTRADIOL VALERATE

DMF 33791978

ASPEN OSS BVESTRADIOL VALERATE

DMF 122681996

VALDEPHARMESTRADIOL VALERATE

DMF 239482010

LUPIN LTDESTRADIOL VALERATE USP

DMF 258542012

STEROID SPAESTRADIOL VALERATE

DMF 395942024

ROUSSELL UCLAFInactiveESTRADIOL VALERATE

DMF 30721977

GEDEON RICHTER PLCInactiveESTRADIOL VALERATE

DMF 245532011

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (3)

Sort:

#001 — 10MG/ML

0 patents0 exclusivities▴

INJECTABLE;INJECTION | Approved: Oct 4, 2007

No patent or exclusivity listings for this strength.

#002 — 20MG/ML

0 patents0 exclusivities▾

INJECTABLE;INJECTION | Approved: Oct 4, 2007

#003 — 40MG/ML

0 patents0 exclusivities▾

INJECTABLE;INJECTION | Approved: Oct 4, 2007